Cargando…

Survival analysis of patients with advanced non‐small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi‐center retrospective study

BACKGROUND: The study was conducted to assess differences in overall survival (OS) in patients with non‐small cell lung cancer (NSCLC) receiving different treatment modalities of tyrosine kinase inhibitors (TKIs). METHODS: A total of 463 NSCLC patients receiving TKI treatment were included. OS was c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Qingming, Guan, Maojing, Wang, Yong, Xu, Congjing, Tang, Lei, Fu, Wenhua, Bi, Minghong, Sun, Xiang, Gu, Kangsheng, Pang, Dongsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792746/ https://www.ncbi.nlm.nih.gov/pubmed/29266865 http://dx.doi.org/10.1111/1759-7714.12577

Ejemplares similares

AB011. Thymoma in patient receiving tyrosine kinase inhibitor (TKI) treatment: morphological aspects and surgical approach
por: Cattaneo, Margherita, et al.
Publicado: (2022)

Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity
por: Gu, Xiaoying, et al.
Publicado: (2021)

Analysis of the relationship between Ki-67 expression and chemotherapy and prognosis in advanced non-small cell lung cancer
por: Wang, Diming, et al.
Publicado: (2020)

PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET
por: van Dongen, Guus A. M. S., et al.
Publicado: (2012)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2022)

Anti-Anaplastic Thyroid Cancer (ATC) Effects and Mechanisms of PLX3397 (Pexidartinib), a Multi-Targeted Tyrosine Kinase Inhibitor (TKI)
por: Luo, Jingtao, et al.
Publicado: (2022)

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs
por: Breccia, Massimo, et al.
Publicado: (2014)

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)

Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS
por: Riccetti, Nicola, et al.
Publicado: (2022)

Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report
por: Lee, Sanghun, et al.
Publicado: (2018)

Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI
por: Lin, Liping, et al.
Publicado: (2018)

Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study
por: Wu, Chia-Che, et al.
Publicado: (2019)

Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
por: Kim, Sungkyoung, et al.
Publicado: (2014)

A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro
por: Lee, Yura, et al.
Publicado: (2016)

Myocardial Infarction after Long-Term Treatment with a Tyrosine Kinase Inhibitor (TKI) with Anti-VEGF Receptor Activity
por: Paschke, L., et al.
Publicado: (2019)

Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?
por: Fontes-Sousa, Mário, et al.
Publicado: (2022)

The assessment of side effects of tyrosine kinase inhibitors (TKI) applied in patients with advanced thyroid cancer (TC) - one centre experience
por: Krajewska, Jolanta, et al.
Publicado: (2013)

Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer
por: Wei, Zhangjing, et al.
Publicado: (2017)

Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
por: Cutica, Ilaria, et al.
Publicado: (2022)

Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma
por: Verma, Akash, et al.
Publicado: (2016)

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
por: Tong, Xuexia, et al.
Publicado: (2019)

Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer
por: Sahin, Katherine B., et al.
Publicado: (2021)

Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis
por: Rinninella, Emanuele, et al.
Publicado: (2020)

Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance
por: Imeri, Jusuf, et al.
Publicado: (2023)

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
por: Ogura, Hayato, et al.
Publicado: (2017)

1790 Targeting filarial kinases with human homologues: repurposed, orally available, approved tyrosine kinase inhibitors (TKI) act as micro- and macrofilaricidal agents at concentrations easily achievable in vivo
por: O'connell, Elise, et al.
Publicado: (2014)

Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
por: Rychter, Anna, et al.
Publicado: (2017)

TKI safety
por: Hjorth-Hansen, Henrik
Publicado: (2019)

Drug Therapy in the Progressed CML Patient with multi-TKI Failure
por: Haznedaroglu, Ibrahim C.
Publicado: (2015)

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
por: Creelan, Ben C., et al.
Publicado: (2019)

Tyrosine kinase c-Abl regulates the survival of plasma cells
por: Li, Yan-Feng, et al.
Publicado: (2017)

Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors—A Retrospective Multi-Center Registry Analysis
por: Koehler, Viktoria Florentine, et al.
Publicado: (2022)

Rechallenge with Multi-Targeted Tyrosine Kinase Inhibitors in Patients with Advanced Soft Tissue Sarcoma: A Single-Center Experience
por: Liu, Jie, et al.
Publicado: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors
por: Liu, Yang, et al.
Publicado: (2022)

Targeting Bruton’s tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study
por: Guan, Wenxue, et al.
Publicado: (2022)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC
por: Zhang, Yongchang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ama1b7nvle66ikj1gn8979vu8